Comparison · NCT00657150-4a496049
Dabigatran 220mg vs Enoxaparin: Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dabigatran 220mg vs Enoxaparin: Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period. Trial comparisons, record NCT00657150-4a496049. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00657150-4a496049
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.077 | 0.0604 | 0.0977 | wilson | |
| Risk in group 2 | 0.0878 | 0.07 | 0.11 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0108 | -0.0382 | 0.0165 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.877 | 0.631 | 1.22 | log | |
| Odds ratio, group 1 over group 2 | 0.867 | 0.605 | 1.24 | log | |
| Number needed to treat, for one fewer participant with the outcome on Dabigatran 220mg than on Enoxaparin | 92.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dabigatran 220mg | qd (once daily) oral | 61 | 792 | OG000 |
| Group 2 | Enoxaparin | 40mg qd (once daily) subcutaneous | 69 | 786 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period
- Description
Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).~All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients.
- Time frame
- 28-35 days
- Population
Full Analysis Set (randomised, had taken at least 1 dose of oral or subcutaneous trial medication, had undergone surgery, had evaluable negative venogram for both distal and proximal DVT in both legs or positive venography in any 1 segment of 1 or both legs, or confirmed symptomatic DVT, PE or death during the treatment period.)
Source ClinicalTrials.gov
Trial
- Title
- Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty
- NCT number
- NCT00657150
- Phases
- PHASE3
- Conditions
- Venous Thromboembolism
- Interventions
- Enoxaparin, Dabigatran etexilate
- Lead sponsor
- Boehringer Ingelheim
- Results first posted
- 2010-12-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00657150?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00657150-4a496049